The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI regimen as second- and third-line chemotherapy for metastatic biliary tract or pancreatic cancer.
Fernanda Navarro Loiola
No relevant relationships to disclose
Marcos Pedro Guedes Camandaroba
No relevant relationships to disclose
Viviane Teodoro Oliveira Fernandes
No relevant relationships to disclose
Augusto Akikubo Rodrigues Pereira
No relevant relationships to disclose